amyloid plaque clearance
FIGURE 5 · Panel Time_to_achieve_amyloid_plaque_clearance
Panel Time_to_achieve_amyloid_plaque_clearance 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ivelina Gueorguieva, Kay Chow, Laiyi Chua, Sergey Shcherbinin, Jennifer A Zimmer, Cynthia D Evans, Hong Wang, Emel Serap Monkul Nery, Dawn A Brooks, John R Sims
Alzheimers Dement 21(7) e70491
INTRODUCTION: These analyses aimed to identify factors impacting donanemab exposure, amyloid plaque, and clinical efficacy in early symptomatic Alzheimer's disease using a population pharmacokinetic/pharmacodynamic (PK/PD) approach. METHODS: Analyses included donanemab trial participants (NCT02624778; NCT03367403; NCT04640077; NCT04437511). Dose- and exposure-response relationships were characterized relative to amyloid plaque lowering using indirect response PK/PD and disease progression models. RESULTS: Donanemab population PK was described by a biphasic distribution with an estimated terminal elimination half-life of approximately 12.1 days for a typical participant (72 kg body weight, 1:2560 maximum antidrug antibody [ADA] titer). Amyloid reduction was associated with maintaining median serum donanemab concentrations over 15 µg/mL (95% confidence interval: 8.54, 18.0). After completing active treatment, simulations showed an estimated plaque reaccumulation rate (median, 95% confidence interval) of 2.8 (2.16, 3.11) Centiloids/year. The donanemab disease progression model showed a clear treatment effect. DISCUSSION: These donanemab models can inform dosing strategies in future clinical trials. HIGHLIGHTS: Weight-based and flat dosing had similar exposure metrics; flat dosing was adopted. Donanemab exposure was influenced by weight and titer (not clinically relevant). 2.8 Centiloids/year amyloid reaccumulation rate observed upon donanemab treatment completion. Around 30% reduction in disease progression rate on treatment for integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB).
1 个 Figure · 1 个 KM 面板
FIGURE 5 Time to achieve amyloid plaque clearance stratified by baseline amyloid level. Percentage of participants achieving amyloid plaque clearance ( < 24.1 Centiloids) by duration on treatment and by quartiles of baseline amyloid PET, assessed using the treatment exposure‐response model. Median (95% confidence interval) is represented by the solid line and shaded area. PET, positron emission tomography; Q, quartiles.
FIGURE 5 · Panel Time_to_achieve_amyloid_plaque_clearance
Panel Time_to_achieve_amyloid_plaque_clearance 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。